Front. Neurosci.: Rifampicin and resveratrol can be combined to treat dementia

The main clinical symptom of some neurodegenerative diseases is dementia, including Alzheimer's disease (AD), frontotemporal dementia (FTD) and dementia with Lewy bodies (DLB)

A research team from the Graduate School of Medicine at Osaka City University previously discovered through a mouse study that the antibiotic rifampicin can remove oligomers in the brain and improve cognitive function

Resveratrol is a naturally occurring antioxidant in plants and is used as a supplement in Europe and the United States

The research team used Alzheimer’s disease, frontotemporal dementia, and Lewy body dementia mouse models as research objects.

In addition, the levels of liver enzymes in the blood (one of the markers of liver damage that usually increase after the use of rifampicin) remained normal in the fixed-dose combination

The results of this study will be published online in Frontiers in Neuroscience on December 13, 2021

First author Tomohiro Umeda said: “The number of dementia patients worldwide has been increasing, and some sources predict that the number of dementia patients will double every 20 years

According to their previous research experience, nasal administration of a fixed-dose drug combination can increase the transfer of drugs to the brain, further improving safety and efficacy

Professor Tomiyama said: "The adult body dose is 0.

The startup company Medilabo RFP, a spin-off of the research team, is currently developing a fixed-dose nasal spray of rifampicin and resveratrol

###

Oligomer-Targeting Prevention of Neurodegenerative Dementia by Intranasal Rifampicin and Resveratrol Combination – A Preclinical Study in Model Mice

Front.